Chemicals · Founded 1943 · www.tcmlimited.in · BSE 524156 · · ISIN INE034F01010
No Notes Added Yet
Business
TCM Ltd. primarily manufactures and sells industrial chemicals. Its core products include Copper Oxychloride (a fungicide used in agriculture), Sodium Hydrosulphite (a reducing agent widely used in the textile, paper, and sugar industries), and Sulphuric Acid (a fundamental industrial chemical). The company also has a legacy business segment involved in tea cultivation and sales. TCM Ltd. generates revenue by manufacturing and supplying these chemicals to various industrial and agricultural clients, as well as by selling tea.
Revenue Mix
Chemicals Division: This segment focuses on the manufacturing and sale of Copper Oxychloride, Sodium Hydrosulphite, and Sulphuric Acid. Given the company's sector classification, this is presumed to be the primary revenue driver.
Plantations Division: This segment encompasses the cultivation and sale of tea.
Specific revenue contributions for each segment are not publicly available without detailed financial report analysis.
Industry
The Indian chemicals industry is diverse, comprising a mix of large integrated players and numerous specialized manufacturers. TCM Ltd. operates in niche areas within the industrial and agrochemical segments. It is positioned as a specialized producer of specific compounds like Copper Oxychloride and Sodium Hydrosulphite. The company likely competes on product quality, supply reliability, and established customer relationships rather than broad scale, generally serving specific segments of the agricultural and industrial sectors.
MOAT
Specialization and Expertise: With a long operational history since 1943, TCM Ltd. has accumulated significant technical expertise in the manufacturing processes of its specific chemical products.
Established Customer Relationships: Its long presence in the market likely translates to established relationships with industrial buyers and distributors.
Barriers to Entry: The chemical manufacturing sector typically involves substantial capital expenditure, specialized technical know-how, and adherence to stringent environmental and safety regulations, which can act as a barrier for new entrants in its product lines.
Growth Drivers
End-User Industry Growth: Increased demand from the agriculture sector (for fungicides), and the textile, paper, and sugar industries (for reducing agents) will drive growth for its chemical products.
Capacity Expansion: Any strategic investments in expanding manufacturing capacity for its key chemicals could lead to higher sales volumes.
Operational Efficiencies: Improvements in manufacturing processes and cost optimization can enhance profitability and support sustainable growth.
Export Market Penetration: Tapping into international markets for its specialized chemicals could open new revenue streams.
Risks
Raw Material Price Volatility: Fluctuations in the cost of key raw materials (e.g., copper, sulfur, various chemical feedstocks) can significantly impact profit margins.
Environmental & Regulatory Risks: Stricter environmental regulations, increased compliance costs, or potential legal issues related to chemical manufacturing could affect operations and profitability.
Competition: Intense competition from both domestic and international chemical manufacturers, including imports, could pressure pricing and market share.
Technological Obsolescence: The emergence of new, more efficient, or environmentally friendlier alternatives to its existing chemical products could reduce demand.
Economic Downturns: A slowdown in industrial activity or agricultural output could lead to reduced demand for its chemicals.
Agricultural Dependency: Demand for Copper Oxychloride is directly linked to agricultural cycles, crop health, and prevailing market conditions in farming.
Management & Ownership
TCM Ltd. is a publicly listed company. Its ownership is primarily led by the promoter group, which appears to be the Maman family/group, indicative of a promoter-driven management structure. Detailed information on individual management quality or specific institutional ownership breakdown is not immediately available without in-depth financial reports.
Outlook
TCM Ltd. benefits from its long operational history and specialization in certain chemical products essential for specific industrial and agricultural applications. Its established position provides a degree of stability and resilience in its core chemical segments. However, the company faces inherent challenges common to the chemical industry, including volatility in raw material prices and the need to comply with evolving environmental regulations. The legacy tea business introduces additional exposure to agricultural commodity risks and climatic factors. Future performance will largely depend on its ability to manage input costs, maintain operational efficiencies, navigate competitive pressures, and potentially capitalize on demand growth from its end-user industries.
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Sales | 9 | 5 | 7 | 6 | 8 | 3 | 6 | 6 | 5 | 5 |
| Other Income | 0 | 0 | 0 | 0 | 4 | 0 | 1 | 0 | 0 | 0 |
| Total Income | 9 | 5 | 7 | 6 | 12 | 3 | 7 | 6 | 5 | 5 |
| Total Expenditure | 9 | 6 | 7 | 7 | 8 | 5 | 7 | 6 | 6 | 6 |
| Operating Profit | -0 | -1 | -1 | -1 | 4 | -2 | -0 | -0 | -1 | -1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -0 | -1 | -1 | -1 | 4 | -2 | -1 | -1 | -2 | -2 |
| Provision for Tax | 0 | 0 | 0 | 0 | -0 | -0 | 0 | 0 | 0 | 0 |
| Profit After Tax | -0 | -1 | -1 | -1 | 4 | -2 | -1 | -1 | -2 | -2 |
| Adjustments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -0 | 0 |
| Profit After Adjustments | -0 | -1 | -1 | -1 | 4 | -2 | -1 | -1 | -2 | -2 |
| Adjusted Earnings Per Share | -0.5 | -1.3 | -0.8 | -1.2 | 5.4 | -3 | -1 | -1.5 | -2.2 | -2.1 |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
| Net Sales | 0 | 1 | 4 | 4 | 7 | 32 | 26 | 22 |
| Other Income | 0 | 1 | 1 | 1 | 0 | 0 | 4 | 1 |
| Total Income | 0 | 2 | 5 | 4 | 7 | 33 | 30 | 23 |
| Total Expenditure | 1 | 2 | 5 | 8 | 11 | 34 | 28 | 25 |
| Operating Profit | -1 | 0 | 0 | -3 | -4 | -2 | 2 | -2 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | -3 | 0 | 0 | 0 | 0 |
| Profit Before Tax | -1 | 0 | 0 | -6 | -4 | -2 | 1 | -6 |
| Provision for Tax | 0 | 0 | 0 | -0 | -0 | 0 | -0 | 0 |
| Profit After Tax | -1 | 0 | 0 | -6 | -4 | -2 | 1 | -6 |
| Adjustments | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Profit After Adjustments | -1 | 0 | 0 | -5 | -4 | -2 | 2 | -6 |
| Adjusted Earnings Per Share | -1.7 | 0.6 | 0.2 | -9.4 | -5.4 | -2.6 | 2.2 | -6.8 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -19% | 87% | 92% | 0% |
| Operating Profit CAGR | 0% | 0% | 0% | 0% |
| PAT CAGR | 0% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | 9% | -3% | -1% | 6% |
| ROE Average | 5% | -6% | -4% | -3% |
| ROCE Average | 6% | -5% | -27% | -20% |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Shareholder's Funds | 32 | 32 | 33 | 25 | 31 | 29 | 31 |
| Minority's Interest | 0 | 0 | 0 | -1 | -1 | -1 | -1 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 20 | 20 | 20 | 20 | 20 | 20 | 0 |
| Total Current Liabilities | 17 | 13 | 15 | 17 | 19 | 36 | 47 |
| Total Liabilities | 69 | 65 | 68 | 61 | 69 | 84 | 76 |
| Fixed Assets | 58 | 58 | 59 | 55 | 36 | 17 | 9 |
| Other Non-Current Assets | 2 | 2 | 3 | 2 | 4 | 1 | 7 |
| Total Current Assets | 9 | 5 | 6 | 5 | 9 | 45 | 42 |
| Total Assets | 69 | 65 | 68 | 61 | 69 | 84 | 76 |
| #(Fig in Cr.) | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Opening Cash & Cash Equivalents | 0 | 4 | 0 | 0 | 0 | 0 | 0 |
| Cash Flow from Operating Activities | -2 | -1 | 0 | -4 | -11 | 2 | -10 |
| Cash Flow from Investing Activities | 0 | 0 | -1 | 4 | 6 | -1 | -0 |
| Cash Flow from Financing Activities | 5 | -3 | 0 | 0 | 5 | -1 | 10 |
| Net Cash Inflow / Outflow | 4 | -4 | 0 | 0 | -0 | 0 | 0 |
| Closing Cash & Cash Equivalent | 4 | 0 | 0 | 0 | 0 | 0 | 0 |
| # | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|
| Earnings Per Share (Rs) | -1.74 | 0.56 | 0.22 | -9.43 | -5.35 | -2.61 | 2.16 |
| CEPS(Rs) | -1.73 | 0.57 | 0.27 | -10.47 | -5.21 | -2.66 | 2.34 |
| DPS(Rs) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Book NAV/Share(Rs) | -53.17 | -51.87 | -51.65 | 46.49 | 41.11 | 38.5 | 40.81 |
| Core EBITDA Margin(%) | -218.08 | -90.44 | -19.16 | -112.59 | -49.94 | -6.91 | -8.25 |
| EBIT Margin(%) | -208.51 | 33.73 | 9.16 | -165.08 | -54.71 | -6.5 | 7.58 |
| Pre Tax Margin(%) | -239.33 | 33.1 | 8.87 | -165.46 | -58.46 | -6.98 | 5.25 |
| PAT Margin (%) | -239.33 | 33.1 | 2.79 | -165.4 | -58.14 | -7.1 | 5.38 |
| Cash Profit Margin (%) | -238.35 | 33.71 | 3.51 | -160.53 | -53.07 | -6.18 | 6.73 |
| ROA(%) | -1.37 | 0.45 | 0.18 | -9.1 | -6.56 | -3 | 1.75 |
| ROE(%) | 0 | 0 | 0 | 0 | -15.24 | -7.69 | 4.72 |
| ROCE(%) | 0 | 0 | 0 | -123.47 | -12.55 | -6.84 | 5.57 |
| Receivable days | 1393.38 | 653.71 | 184.76 | 226.81 | 163.72 | 74.74 | 107.2 |
| Inventory Days | 1565.51 | 636.24 | 168.31 | 193.84 | 127.99 | 194.58 | 414.19 |
| Payable days | 2568.13 | 1784.19 | 703.75 | 306.95 | 57.75 | 32.26 | 53.44 |
| PER(x) | 0 | 0 | 115 | 0 | 0 | 0 | 16.58 |
| Price/Book(x) | -0.56 | 0 | -0.48 | 0.65 | 0.81 | 1.43 | 0.88 |
| Dividend Yield(%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EV/Net Sales(x) | 45.17 | 9.81 | 4.56 | 6.4 | 3.54 | 1.27 | 1.44 |
| EV/Core EBITDA(x) | -21.77 | 28.58 | 46.09 | -7.3 | -7.12 | -22.74 | 16.16 |
| Net Sales Growth(%) | 0 | 132.34 | 361.81 | -16.36 | 106.71 | 338.67 | -19.32 |
| EBIT Growth(%) | 0 | 137.58 | 25.42 | -1607.27 | 31.5 | 47.91 | 194.19 |
| PAT Growth(%) | 0 | 132.13 | -61.13 | -5065.54 | 27.34 | 46.41 | 161.13 |
| EPS Growth(%) | 0 | 132.08 | -61.13 | -4444.94 | 43.2 | 51.3 | 182.65 |
| Debt/Equity(x) | -0.19 | -0.2 | -0.21 | 0.26 | 0.05 | 0.01 | 0.37 |
| Current Ratio(x) | 0.51 | 0.38 | 0.39 | 0.26 | 0.5 | 1.25 | 0.9 |
| Quick Ratio(x) | 0.41 | 0.27 | 0.24 | 0.18 | 0.3 | 0.41 | 0.29 |
| Interest Cover(x) | -6.76 | 53.52 | 31.4 | -434.65 | -14.59 | -13.47 | 3.25 |
| Total Debt/Mcap(x) | 0.33 | 0 | 0.43 | 0.4 | 0.06 | 0.01 | 0.42 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 49.51 | 49.51 | 49.51 | 49.51 | 49.51 | 49.51 | 49.51 | 49.51 | 49.51 | 49.51 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 7.71 | 7.44 | 7.44 | 7.44 | 7.44 | 7.44 | 7.44 | 7.44 | 7.44 | 7.44 |
| Public | 42.78 | 43.05 | 43.05 | 43.05 | 43.05 | 43.05 | 43.05 | 43.05 | 43.05 | 43.05 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.37 | 0.37 | 0.37 | 0.37 | 0.37 | 0.37 | 0.37 | 0.37 | 0.37 | 0.37 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 |
| Public | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | -19% | +87% | +92% | — |
| Operating Profit CAGR | — | — | — | — |
| PAT CAGR | — | — | — | — |
| Share Price CAGR | +9% | -3% | -1% | +6% |
| ROE Average | +5% | -6% | -4% | -3% |
| ROCE Average | +6% | -5% | -27% | -20% |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 49.51 | 49.51 | 49.51 | 49.51 | 49.51 | 49.51 | 49.51 | 49.51 | 49.51 | 49.51 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 7.71 | 7.44 | 7.44 | 7.44 | 7.44 | 7.44 | 7.44 | 7.44 | 7.44 | 7.44 |
| Public | 42.78 | 43.05 | 43.05 | 43.05 | 43.05 | 43.05 | 43.05 | 43.05 | 43.05 | 43.05 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.37 | 0.37 | 0.37 | 0.37 | 0.37 | 0.37 | 0.37 | 0.37 | 0.37 | 0.37 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 | 0.06 |
| Public | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 | 0.32 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 | 0.75 |
* The pros and cons are machine generated.
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
Your relationship manager will connect with you shortly.